The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for >2.4 million infections and >150 000 deaths worldwide, with the United States now having the largest number of reported cases.1 It is suggested in available data that most children have mild disease and that children with severe disease appear to be younger (usually <1 years of age)2 or have preexisting medical conditions.3 Mild thrombocytopenia has been seen in adult patients with severe coronavirus disease 2019 (COVID-19),4 and there is 1 report of immune thrombocytopenia (ITP) associated with COVID-19 in an adult patient with underlying autoimmune hypothyroidism.5 We report a case of severe COVID-19 in a previously healthy 12-year-old child presenting with respiratory failure and severe thrombocytopenia.
On physical examination, she had dyspnea, diminished breath sounds diffusely, and petechiae. The rest of her examination was unremarkable. Chest radiograph revealed bilateral diffuse airspace opacities and small pleural effusion.

Laboratory findings on admission were remarkable for severe thrombocytopenia, lymphopenia, and elevated inflammatory markers (C-reactive protein [CRP], procalcitonin, and ferritin) (Table 1). The only abnormality on peripheral blood smear was severe macrothrombocytopenia. The results for nasopharyngeal swab respiratory viral panel by multiplex polymerase chain reaction (PCR) for 16 common pathogens such as rhinovirus and influenza were negative.

**HOSPITALIZATION COURSE**

The patient was admitted to the ICU on high-flow nasal cannula but subsequently required intubation and mechanical ventilation on 100% oxygen on hospital day (HD) 1. She had continued desaturations and so was started on inhaled nitric oxide (iNO) with improvement in PaO₂ and oxygen saturations (oxygen index was 30 before and 9.7 after iNO). Empirical antibiotics for presumed sepsis were initiated. Because of the risk for bleeding with concern for ITP, intravenous immunoglobulin (IVIg) was given on HDs 1 and 2 (1 g/kg per dose) along with methylprednisolone (1.5 mg/kg) on HD 2 with good recovery of platelets (143 × 10⁹/L on HD 4). Azithromycin was started on HD 2 for 3 days as an antiinflammatory agent in the setting of acute respiratory distress syndrome (ARDS).

A summary of the hospital course and treatments is shown in Fig 1. A nasopharyngeal SARS-CoV-2 real-time reverse transcription PCR test was sent after admission and returned with positive results on HD 4. The patient did not have any known exposure to patients with COVID-19 or recent travel. Hydroxychloroquine was started (400 mg twice daily on HD 4 followed by 200 mg twice daily until HD 7) for off-label treatment of severe COVID-19 infection. A hyperinflammation workup was performed after the SARS-CoV-2 testing resulted positive to guide additional immunomodulatory therapy (Table 1). Attempts were made to wean ventilator support and iNO but were unsuccessful. On HD 7, because of continued fever, ARDS and elevated inflammatory markers including interleukin-6 (IL-6), 2 doses of tocilizumab (8 mg/kg 12 hours apart), a humanized monoclonal IL-6 receptor antibody were given, and she was changed to airway pressure release ventilation for enhanced ARDS management. We obtained permission for compassionate use of remdesivir, which was also started on HD 7 (200 mg on HD 7 followed by 100 mg daily). On HD 8, the patient had significant clinical (oxygen index improved from 7.9 to 5.5) and radiographic (Fig 2) improvement and was weaned off iNO. We discontinued remdesivir on HD 12 because of mildly elevated transaminases per compassionate use guidelines, and after a cautious wean of ventilatory support to avoid risk of reintubation per available guidance at the time, the patient was extubated on HD 14. On HD 24, the patient was discharged from the hospital after undergoing a short inpatient rehabilitation stay.

### Table 1 Admission and Hyperinflammation Laboratory Results

<table>
<thead>
<tr>
<th>Laboratory Measures</th>
<th>Value</th>
<th>Reference Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission (HD 0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White blood cell count, per μL</td>
<td>5470</td>
<td>4500–13500</td>
</tr>
<tr>
<td>Absolute lymphocyte count, per μL</td>
<td>711 (L)</td>
<td>1485–6480</td>
</tr>
<tr>
<td>Hemoglobin, g/dL</td>
<td>12.3</td>
<td>12–16</td>
</tr>
<tr>
<td>Platelet count, &gt;103×10⁹/μL</td>
<td>&lt;10 (L)</td>
<td>150–450</td>
</tr>
<tr>
<td>Prothrombin time, s</td>
<td>15.3</td>
<td>12.8–15.9</td>
</tr>
<tr>
<td>Activated partial thromboplastin time, s</td>
<td>55.6 (H)</td>
<td>26–38</td>
</tr>
<tr>
<td>Fibrinogen, mg/dL</td>
<td>424 (H)</td>
<td>200–400</td>
</tr>
<tr>
<td>Sodium, mmol/L</td>
<td>132 (L)</td>
<td>134–143</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>0.69</td>
<td>0.30–0.80</td>
</tr>
<tr>
<td>Total bilirubin, mg/dL</td>
<td>0.8</td>
<td>0.2–1.0</td>
</tr>
<tr>
<td>Aspartate aminotransferase, U/L</td>
<td>37 (H)</td>
<td>17–33</td>
</tr>
<tr>
<td>Alanine aminotransferase, U/L</td>
<td>25</td>
<td>11–33</td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>11.5 (H)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Procalcitonin, ng/mL</td>
<td>0.83 (H)</td>
<td>&lt;0.10</td>
</tr>
<tr>
<td>Ferritin, ng/mL</td>
<td>481 (H)</td>
<td>14–79</td>
</tr>
<tr>
<td>HD 4*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>8.3 (H)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Ferritin, ng/mL</td>
<td>800 (H)</td>
<td>14–79</td>
</tr>
<tr>
<td>IL-2 receptor, pg/mL</td>
<td>910</td>
<td>&lt;1033</td>
</tr>
<tr>
<td>IL-6, pg/mL</td>
<td>10 (H)</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Interferon-γ, pg/mL</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>IL-10, pg/mL</td>
<td>&lt;5</td>
<td>&lt;18</td>
</tr>
<tr>
<td>HD 7*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/dL</td>
<td>10.3 (H)</td>
<td>&lt;1.0</td>
</tr>
<tr>
<td>Ferritin, ng/mL</td>
<td>436 (H)</td>
<td>14–79</td>
</tr>
<tr>
<td>IL-2 receptor, pg/mL</td>
<td>1486 (H)</td>
<td>&lt;1033</td>
</tr>
<tr>
<td>IL-6, pg/mL</td>
<td>34 (H)</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Interferon-γ, pg/mL</td>
<td>10 (H)</td>
<td>&lt;5</td>
</tr>
<tr>
<td>IL-10, pg/mL</td>
<td>9</td>
<td>&lt;18</td>
</tr>
<tr>
<td>CXCL9, pg/mL</td>
<td>248 (H)</td>
<td>&lt;121</td>
</tr>
<tr>
<td>IL-18, pg/mL</td>
<td>1184 (H)</td>
<td>89–540</td>
</tr>
</tbody>
</table>

CXCL9, C-X-C motif chemokine 9; H, high; IL-2, interleukin-2; IL-10, interleukin-10; IL-18, interleukin-18; L, low.

* Drawn on HD 4.

† Drawn before administration of tocilizumab on HD 7.
DISCUSSION
We report the successful management of a critically ill child with COVID-19 in the United States. In contrast to children with severe COVID-19 from the People’s Republic of China, our patient was older and had no previous medical history. Her presentation with severe thrombocytopenia raised the concern for acute ITP given the degree of thrombocytopenia, peripheral blood smear, and lack of other physical examination findings such as organomegaly. Other causes for thrombocytopenia were considered in the differential including thrombosis, microangiopathic hemolytic anemia, hemophagocytic lymphohistiocytosis, hypersplenism, ARDS, the coronavirus infection itself, and medications. ITP is a diagnosis of exclusion, and although the other causes of thrombocytopenia could not be ruled out with complete certainty, the clinical and laboratory findings were not supportive of these alternative diagnoses. Therefore, her thrombocytopenia was treated as ITP with standard first-line treatments, IVIg, and corticosteroids, with good recovery of her platelets. Although mild thrombocytopenia has been reported in older patients with COVID-19, our patient’s presentation with profound thrombocytopenia was atypical. Similar to adult patients, our patient’s thrombocytopenia was associated with a more severe disease course.

After our patient’s SARS-CoV-2 reverse transcription PCR test results returned positive, hydroxychloroquine was initiated on the basis of preliminary reports available at the time suggesting enhanced viral clearance in vitro and in a small case series of adult patients with COVID-19. However, it is suggested in recent evidence that hydroxychloroquine provides no benefit, and our patient showed no improvement with its use. Remdesivir is an adenosine analog that inhibits viral replication with broad antiviral activity including against SARS-CoV-2 in vitro. Although there are currently no approved therapies for SARS-CoV-2, preliminary evidence from a case series of adult patients seems to suggest some clinical improvement with the use of remdesivir, but results from placebo-controlled randomized trials are still pending. Our patient received remdesivir under compassionate use and tolerated it well aside from mildly
elevated transaminases, which were also reported in adults. The patient had clear signs of clinical improvement after remdesivir; however, its role as a single agent is unclear because it was given in combination with tocilizumab.

Because of the severity of the patient’s severe acute respiratory syndrome in an otherwise healthy child, a hyperinflammation workup was initiated to guide additional immunomodulatory therapy. It is suggested in adult data that cytokine storm syndrome may play a role in the morbidity and mortality in a subset of patients with COVID-19. IL-6 is a proinflammatory cytokine implicated in cytokine release syndrome (CRS), which is sometimes seen after chimeric antigen T-cell therapies for malignancies. In a retrospective review of 150 hospitalized adult patients with COVID-19, CRP, another marker of acute inflammation, and IL-6 were significantly higher in those patients who died than in those who were discharged from the hospital. Elevated IL-6 levels were also reported in 2 of the 3 critically ill children with COVID-19 from Wuhan, China.

Tocilizumab is a humanized IL-6 receptor monoclonal antibody approved by the Food and Drug Administration to treat rheumatologic disease as well as CRS. Reports in adults have revealed a potential benefit of tocilizumab in COVID-19 and clinical trials in adult patients with COVID-19 pneumonia are ongoing. Our patient’s inflammatory laboratories before administration of tocilizumab were elevated (Table 1) but not to the extent in other literature. Because our patient received other immunomodulatory medications (IVIg and corticosteroids) early in her disease course for treatment of presumed ITP, this may have reduced the inflammation to some degree as evidenced by declining markers of inflammation from HDs 3 to 5. Although our patient was treated with multiple SARS-CoV-2-directed (hydroxychloroquine and remdesivir) as well as ARDS-directed therapies (iNO and airway pressure release ventilation), her sustained improvement after the administration of tocilizumab with normalization of inflammatory markers and extubation within 7 days is consistent with results of its use in CRS. Our patient tolerated it well without any significant toxicities aside from mildly elevated transaminases, which may have been precipitated or exacerbated by concomitant administration of remdesivir.

In addition to tocilizumab, other cytokine-directed therapies, such as sarilumab, another IL-6 receptor antibody, anakinra, an IL-1 receptor antagonist, and emapalumab, an interferon-γ antibody, are all under investigation in clinical trials for the management of COVID-19-associated hyperinflammation and acute lung injury. We acknowledge the limitations of drawing treatment conclusions from our single case, but given that severe COVID-19 is uncommon in children and current clinical trials for immunomodulatory drugs are being conducted only in adults, our report serves to inform the pediatric community about the potential use of antiviral agents such as remdesivir and immunomodulatory agents such as tocilizumab in severe pediatric cases.

CONCLUSIONS

We report a case of severe pediatric COVID-19 in the United States in an otherwise healthy child presenting with severe thrombocytopenia and ARDS. Consistent with adult literature on COVID-19, our patient’s severe disease course was associated with thrombocytopenia and elevated inflammatory markers. The patient’s severe respiratory disease did not improve on IVIg, steroids, azithromycin, and hydroxychloroquine. We did observe a temporal clinical improvement after the administration of tocilizumab and remdesivir. To the best of our knowledge, there have been no reports to date involving the use of either remdesivir or tocilizumab in pediatric patients with severe COVID-19. Our report contributes to the evolving literature on COVID-19 revealing that although rare, severe COVID-19 does occur in the pediatric age group even in previously healthy children. In addition, with our case, we illustrate that hyperinflammation may be important in the pathophysiology of COVID-19 severe acute respiratory syndrome and that treatment with cytokine-directed agents such as tocilizumab could be considered in critically ill patients. Finally, we advocate for randomized placebo-controlled clinical trials used to study drugs like tocilizumab and remdesivir to include children in addition to adults with COVID-19 given our patient’s presentation and response.

ACKNOWLEDGMENTS

Parental consent was obtained before publication of this report. We thank the patient’s family for allowing us to share this case. We also acknowledge the other clinicians and staff of Children’s Healthcare of Atlanta at Scottish Rite for their commitment to this patient’s and others’ care in the setting of this outbreak.

ABBREVIATIONS

ARDS: acute respiratory distress syndrome
COVID-19: coronavirus disease 2019
CRP: C-reactive protein
CRS: cytokine release syndrome
HD: hospital day
IL-6: interleukin-6
iNO: inhaled nitric oxide
ITP: immune thrombocytopenia
IVIg: intravenous immunoglobulin
PCR: polymerase chain reaction
SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
REFERENCES


Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia
Pratik A. Patel, Shanmuganathan Chandrakasan, Geoffrey E. Mickells, Inci Yildirim, Carol M. Kao and Carolyn M. Bennett
Pediatrics 2020;146; DOI: 10.1542/peds.2020-1437 originally published online May 4, 2020;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/146/1/e20201437

References
This article cites 12 articles, 2 of which you can access for free at:
http://pediatrics.aappublications.org/content/146/1/e20201437#BIBL

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Hematology/Oncology
http://www.aappublications.org/cgi/collection/hematology:oncology
Blood Disorders
http://www.aappublications.org/cgi/collection/blood_disorders_sub
Infectious Disease
http://www.aappublications.org/cgi/collection/infectious_diseases_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml

American Academy of Pediatrics
DEDICATED TO THE HEALTH OF ALL CHILDREN®
Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia
Pratik A. Patel, Shanmuganathan Chandrakasan, Geoffrey E. Mickells, Inci Yildirim, Carol M. Kao and Carolyn M. Bennett
*Pediatrics* 2020;146;
DOI: 10.1542/peds.2020-1437 originally published online May 4, 2020;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/146/1/e20201437